

Correction: Less Radiographic Progression with Adalimumab plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis.

J Rheumatol 2010;37;1367
<http://www.jrheum.org/content/37/6/1367>

1. Sign up for TOCs and other alerts
<http://www.jrheum.org/alerts>
2. Information on Subscriptions
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

Correction

Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. *J Rheumatol* 2009-36:1429-41. (1) In the Results section, page 1431, second column; for MTX monotherapy at Week 104, ACR 20/50/70 response rates should be changed from 86%/66%/49% to 86%/66%/43%. (2) In the first column of page 1432, under the heading “Mean Δ TSS and frequency of radiographic progression by level of ACR response,” the first sentence of the section should read: “The mean Δ TSS values were significantly greater for MTX monotherapy than adalimumab plus MTX for each level of ACR response at Week 26 (except ACR70; Figure 2A) and Week 104 (Figure 2B).” (3) In Table 2, page 1435, first column, DAS28 > 2.6 should be changed to DAS28 < 2.6. We regret the errors.

doi:10.3899/jrheum.081018C2